In 2005, more than 22,000 American women were diagnosed with ovarian cancer and 16,000 women died from the disease. The fi ve-year relative survival rate for stage III and IV disease is 31%, and the fi ve-year relative survival rate for stage I is 95%. Early diagnosis should lower the fatality rate. Unfortunately, early diagnosis is diffi cult because of the physically inaccessible location of the ovaries, the lack of specifi c symptoms in early disease, and the limited understanding of ovarian oncogenesis. Screening tests for ovarian cancer need high sensitivity and specifi city to be useful because of the low prevalence of undiagnosed ovarian cancer. Because currently available screening tests do not achieve high levels of sensitivity and specifi city, screening is not recommended for the general population. The theoretical advantage of screening is much higher for women at high risk (such as those with a strong family history of ovarian cancer and those with BRCA 1 or BRCA 2 mutations). However, even for women at high risk, no prospective studies have shown benefi ts of screening. The public health challenge is that 90% of ovarian cancer occurs in women who are not in an identifi able high-risk group, and most women are diagnosed with advanced-stage disease. Currently available tests (CA-125, transvaginal ultrasound, or a combination of both) lack the sensitivity and specifi city to be useful in screening the general population. Ongoing clinical trials are assessing whether new tumor markers, including those generated by proteomic and genomic studies, will prove useful.
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Ovarian Cancer Screening:
A Look at the Evidence At a Glance ✦ Most ovarian cancer is diagnosed at stage III or IV in women who are not identifi ed as being at high risk for the disease.
✦ Early diagnosis is diffi cult because of the inaccessibility of the ovaries for screening and the vague symptoms of earlystage disease.
✦ Screening is not recommended for the general population because of the high number of false negatives and false positives generated by currently available tests. However, new tumor markers and proteomic analysis are being studied for ovarian cancer screening. IV) have a 31% fi ve-year relative survival rate, and the fi ve-year relative survival rate for early-stage or localized disease (stage I or II) is as high as 95%. Unfortunately, only 29% of ovarian cancers are detected during early stages (American Cancer Society). Women dying from ovarian cancer lose an average of 18 years of life, perhaps the most alarming statistic of all (Duffy, 2001) .
The data suggest that an effective screening test resulting in earlier diagnosis would decrease the fatality rate. However, screening for ovarian cancer is a diffi cult problem (see Figure 1 ) because of the location of the ovaries deep in the pelvis among the viscera. Unlike the circumstances in screening for cervical, vaginal, and vulvar cancers, no direct visualization or tissue sampling is possible in ovarian cancer without invasive procedures. Additionally, symptoms of ovarian cancer are vague and nonspecifi c, and they often do not occur until late in the course of the disease (Wenham, Lancaster, & Berchuck, 2002) . Early signs and symptoms of ovarian cancer include early satiety; mild abdominal discomfort lasting more than four to fi ve days; changes in bowel habits, including diarrhea and constipation; This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.
